NEUMORA THERAPEUTICS, INC. Earnings Per Share (Basic)
NEUMORA THERAPEUTICS, INC. (NMRA) reported Earnings Per Share (Basic) of -$0.23 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.23.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.30.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was $2.46, a 7.69% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.35.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$1.45.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$1.53.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$3.63.
- NEUMORA THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$4.81.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.23 10-Q · filed 2026-08-14 | -$0.53 10-Q · filed 2026-08-14 | $1.79 derived: net income ÷ weighted average shares · filed 2026-08-14 | $1.50 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2026-03-31 | -$0.30 10-Q · filed 2026-05-07 | $2.07 derived: net income ÷ weighted average shares · filed 2026-08-14 | $1.79 derived: net income ÷ weighted average shares · filed 2026-08-14 | $1.50 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-12-31 | $2.46 derived: net income ÷ weighted average shares · filed 2026-04-17 | $2.16 derived: net income ÷ weighted average shares · filed 2026-04-17 | $1.86 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.45 10-K · filed 2026-03-30 |
| 2025-09-30 | -$0.35 10-Q · filed 2025-11-06 | -$0.68 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.10 10-Q · filed 2025-11-06 | $1.56 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-06-30 | -$0.33 10-Q · filed 2026-08-14 | -$0.75 10-Q · filed 2026-08-14 | $1.91 derived: net income ÷ weighted average shares · filed 2026-08-14 | $1.46 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2025-03-31 | -$0.42 10-Q · filed 2026-05-07 | $2.24 derived: net income ÷ weighted average shares · filed 2026-08-14 | $1.79 derived: net income ÷ weighted average shares · filed 2026-08-14 | $1.43 derived: net income ÷ weighted average shares · filed 2026-08-14 |
| 2024-12-31 | $2.66 derived: net income ÷ weighted average shares · filed 2026-04-17 | $2.22 derived: net income ÷ weighted average shares · filed 2026-04-17 | $1.86 derived: net income ÷ weighted average shares · filed 2026-04-17 | -$1.53 10-K · filed 2026-03-30 |
| 2024-09-30 | -$0.45 10-Q · filed 2025-11-06 | -$0.82 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.16 10-Q · filed 2025-11-06 | -$1.86 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$0.37 10-Q · filed 2025-08-06 | -$0.71 10-Q · filed 2025-08-06 | -$1.41 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$2.12 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-03-31 | -$0.34 10-Q · filed 2025-05-12 | -$1.04 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.80 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$2.62 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2023-12-31 | -$0.71 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$1.61 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$2.61 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$3.63 10-K · filed 2025-03-03 |
| 2023-09-30 | -$1.14 10-Q · filed 2024-11-12 | -$2.38 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.59 10-Q · filed 2024-11-12 | -$4.62 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2023-06-30 | -$1.28 10-Q · filed 2024-08-06 | -$2.50 10-Q · filed 2024-08-06 | -$3.50 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$4.57 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2023-03-31 | -$1.22 10-Q · filed 2024-05-07 | -$2.21 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$3.28 derived: net income ÷ weighted average shares · filed 2025-03-03 | |
| 2022-12-31 | -$0.99 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$2.06 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$4.81 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$1.06 10-Q · filed 2023-11-01 | -$3.83 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |